Skip to main content
Premium Trial:

Request an Annual Quote

SynX Shareholders, Ontario Court Okay Nanogen Acquisition

NEW YORK, April 20 (GenomeWeb News) - Nanogen of San Diego and Toronto-based SynX Pharma said today that the Ontario Superior Court of Justice and SynX shareholders have approved Nanogen's all-stock transaction of SynX, which was originally announced in February.

The transaction, valued at approximately CA$16.3 million (US$12 million), is currently scheduled for tomorrow, April 21, 2004, but is still "subject to other regulatory approvals and other customary closing conditions," the companies said.

SynX said that it has approximately 11.4 million shares and share equivalents outstanding, and that it expects each of its shareholders to receive approximately CA$1.426 per SynX share in Nanogen common stock.

The exchange ratio will be determined on the closing date, at which time Nanogen will acquire CA$3.5 million in subordinated secured debentures of SynX in exchange for shares of Nanogen stock.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.